PolyPid Reports Enrollment Of The 100th Patient In Ongoing SHIELD II Phase 3 Trial
The Company intends to conduct an unblinded interim analysis once a total of approximately 400 patients complete their 30-day follow-up, which is expected to occur in mid-2024.